High Mobility Group Protein B1 - Pipeline Review, H2 2016 - Key Vendors are Affibody AB, Bio3 Research & Dicerna Pharmaceuticals - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H2 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for High Mobility Group Protein B1, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Mobility Group Protein B1 and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Affibody AB
  • Bio3 Research S.r.l
  • Dicerna Pharmaceuticals, Inc.
  • Evec, Inc.
  • Ribomic Inc.

Key Topics Covered:

  • Introduction
  • High Mobility Group Protein B1 Overview
  • Therapeutics Development
  • Pipeline Products for High Mobility Group Protein B1 - Overview
  • Pipeline Products for High Mobility Group Protein B1 - Comparative Analysis
  • High Mobility Group Protein B1 - Therapeutics under Development by Companies
  • High Mobility Group Protein B1 - Therapeutics under Investigation by Universities/Institutes
  • High Mobility Group Protein B1 - Pipeline Products Glance
  • Late Stage Products
  • Clinical Stage Products
  • Early Stage Products
  • High Mobility Group Protein B1 - Products under Development by Companies
  • High Mobility Group Protein B1 - Products under Investigation by Universities/Institutes
  • High Mobility Group Protein B1 - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/7g5cw3/high_mobility

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs